| Autor: |
Woo SM; Department of Gastroenterology and Hepatology, MedStar Georgetown University Hospital, 3800 Reservoir Road NW, Washington, DC 20007, USA., Kimchy AV; Department of Internal Medicine, MedStar Georgetown University Hospital, Washington, DC 20007, USA., Sequeira LM; Georgetown University School of Medicine, Washington, DC 20007, USA., Dorris CS; Dahlgren Memorial Library, Georgetown University Medical Center, Washington, DC 20007, USA., He AR; Department of Hematology and Oncology, MedStar Georgetown University Hospital, Washington, DC 20007, USA., Rangnekar AS; MedStar Georgetown Transplant Institute, MedStar Georgetown University Hospital, Washington, DC 20007, USA. |
| Abstrakt: |
Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer-related mortality worldwide, and its incidence has increased rapidly in the United States over the past two decades. Liver transplant is considered curative, but is not always possible, and pre-transplant immunotherapy is of great interest as a modality for downstaging the tumor burden. We present a review of the literature on pre-liver transplant immunotherapy use in patients with HCC. Our literature search queried publications in Ovid MEDLINE, Ovid Embase, and Web of Science, and ultimately identified 24 original research publications to be included for analysis. We found that the role of PD-1 and PD-L1 in risk stratification for rejection is of special interest to researchers, and ongoing randomized clinical trials PLENTY and Dulect 2020-1 will provide insight into the role of PD-1 and PD-L1 in liver transplant management in the future. This literature search and the resulting review represents the most thorough collection, analysis, and presentation of the literature on the subject to date. |
